home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410n.zip
/
M94A2625.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
47 lines
Document 2625
DOCN M94A2625
TI Paediatric European Network for Treatment of AIDS (PENTA). PENTA
Steering Committee.
DT 9412
AU Grosch-Woerner I; Castelli G; Rosado L; Debre M; Gibb DM
SO Int Conf AIDS. 1994 Aug 7-12;10(1):261 (abstract no. PB0472). Unique
Identifier : AIDSLINE ICA10/94369950
AB The PENTA I Trial is a double blind, placebo controlled trial to
determine the efficacy and toxicity of early compared with deferred use
of zidovudine (ZDV) in children with early vertically acquired HIV
disease. The trial is jointly co-ordinated by the MRC HIV Clinical
Trials Centre and the Agence Nationale pour Recherches sur la SIDA,
INSERM, France under the auspices of PENTA. Centres from each of 10
countries link with one of the 2 Trials Centres; randomisation to ZDV
syrup or placebo is performed centrally and follow-up forms are
completed 3-monthly. Children may be transferred to open ZDV if they
progress and all are followed to endpoints of AIDS or death. Over the
first 18 months, 125 of the planned intake of 400 children have been
enrolled from 32 centres in 9 countries. Age at trial entry ranged from
4 months to 11 years and 13% were < 1 year. 27% had CD4 counts below the
normal range at baseline and all but 12% had one or more HIV associated
manifestations. Three children have developed AIDS and 7 have
transferred to open ZDV for disease progression. Severe neutropenia
resulting in dose modification developed in 3 children and in 17, minor
gastrointestinal adverse events have occurred, 3 resulting in
withdrawal. The Data and Safety Monitoring Committee (DSMC) recommended
continuation of the trial in October 1993 and recruitment is being
extended outside Europe to Canada and Brazil. The PENTA 3 Trial is a
phase II trial comparing toxicity and tolerability of ZDV alone, with
ZDV and Dideoxycytidine (ddC), in symptomatic antiretroviral naive
HIV-infected children. It is due to start in 1994 with a planned intake
of 100 children. Centres participating in these two trials will
contribute to a European network for future studies on antiretroviral
and other aspects for both treatment and prophylaxis in children with
HIV infection.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY/
TRANSMISSION Child Child, Preschool Double-Blind Method
Europe/EPIDEMIOLOGY Female Follow-Up Studies Human HIV
Infections/*DRUG THERAPY/MORTALITY/TRANSMISSION Infant Male Survival
Rate Zidovudine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS CLINICAL
TRIAL MEETING ABSTRACT MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).